newsfilter
← Latest News
GlobeNewswire·

Medexus Pharmaceuticals Announces Clear Path to FDA Decision Following medac's Type A Meeting with FDA on Treosulfan

NDA resubmission expected in second calendar quarter 2022 (previously anticipated timeline)Final FDA decision expected 2 to 6 months after NDA resubmissionNo additional Phase III study is required TORONTO and CHICAGO, Dec. 02, 2021 (GLOBE NEWSWIR